Phase 3 study of UX007 in patients with Long-Chain Fatty Acid Oxidation Disorder
Phase of Trial: Phase III
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Triheptanoin (Primary)
- Indications Lipid metabolism disorders
- Focus Therapeutic Use
- Sponsors Ultragenyx Pharmaceutical
- 27 Jul 2017 According to Ultragenyx media release, the company continue to plans for discussion with the regulatory authorities.
- 15 Oct 2015 New trial record
- 13 Oct 2015 According to Ultragenyx media release, design and timing of this study will be provided after discussion with the regulatory authorities in the first half of 2016.